Synsorb - Bericht aus Kanada - 500 Beiträge pro Seite

[Stamoulis]

hier ein Bericht aus Kanada, den ich grad gefunden habe:

(SYBB) SYNSORB Biotech Inc. Announces Sale of INH Technologies Inc. Subsidiary to MDS
TUESDAY, MARCH 07, 2000 8:00 AM
- BusinessWire

CALGARY, Alberta, Mar 7, 2000 (BUSINESS WIRE) -- SYNSORB Biotech Inc. ("SYNSORB") (TSE:SYB., Nasdaq:SYBB) today announced that it has signed an agreement with MDS Inc. to sell SYNSORB`s subsidiary, INH Technologies Inc. ("INH") to MDS Inc. ("MDS") through its MDS Sciex division.

Under the terms of the agreement, MDS has purchased INH for an undisclosed cashpayment. In addition, an agreement has been signed, providing for future milestone and royalty payments. It is expected that a revenue stream to SYNSORB relating to this technology could be generated within 12 months.

"The sale of INH to MDS represents yet another milestone achieved in SYNSORB`s plan to focus solely on the clinical development of our products. Through this sale, SYNSORB has ensured that this outstanding pharmaceutical technology will be developed by a proven leader in this field, while also securing a potential revenue stream from royalties on sales," stated David Cox, Ph.D., President and Chief Executive Officer of SYNSORB. "This transaction further demonstrates SYNSORB`s unwavering commitment to focus on SYNSORB Cd(R) and SYNSORB Pk(R)."

Located in Calgary, INH is a wholly owned subsidiary of SYNSORB. Built around technology acquired from the University of Alberta in 1998, INH is focussed on the
development of equipment and technology designed to assist in the high throughput screening of potential drug compounds. INH uses broad-based technology to probe
interactions between drug targets and combinatorial chemical libraries.

MDS Sciex is a provider of leading-edge mass spectrometry and quadrupole time-of-flight technology to the pharmaceutical and biotechnology industry. MDS Sciex is a
division of MDS Inc. (TSE: MDS.A, MDS.B), an international health and life sciences company based in Canada.

SYNSORB is a Canadian-based pharmaceutical company dedicated to drug development and manufacturing. The Company has two late-stage products, both of
which are based on SYNSORB`s proprietary carbohydrate chemistry platform technology. SYNSORB Cd(R) will commence Phase III trials within the first half of
2000, and is designed to treat recurrent antibiotic-associated diarrhea (CDAD), a common hospital acquired infection. SYNSORB Pk(R) is in Phase III clinical trials,
and is designed to prevent the progression to Hemolytic Uremic Syndrome (HUS) in children who have contracted verotoxigenic E. coli (VTEC) infections, including E.
coli O157:H7. SYNSORB has built a cGMP-compliant manufacturing facility that has
the capacity to meet or exceed the expected global demand for the Company`s products. A pipeline of future products is accessible through SYNSORB`s carbohybrid program.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company`s
control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations
implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the
Company`s registration statement on Form 20 F filed with the Securities and Exchange Commission.

[New World Order]

denke das wir mit synsorb noch viel freude haben werden. habe die jüngste konsolidierung zum aufstocken meiner poaitionen genützt.

cu
dfx

[Stamoulis]

denke daß sie nach jüngster Nasdaq-Entwicklung morgen nocheinmal fallen werden, werde die Gelegenheit nutzen und mich nocheinmal eindecken ;-)